More articles from Preclinical Probes for Oncology

You have access
A new series of PSMA-targeting inhibitors for astatine-211 targeted radionuclide therapy of prostate cancer
Mohamed El Fakiri, Nawal Ayada, Christian Poulie, Marius Müller, Teodor Gamzov, Holger Jensen, Sture Lindegren, Andreas Ingemann, Andreas Kjaer, Ann-Christin Eder, Matthias Eder and Matthias Herth

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2878;
You have access
A preliminary study on noninvasively imaging CAR T cells with PSMA-targeted PET
Xiangming Song, Xiaoying Lv, Yu Long, Yirui Zhang, Zhuoshuo Xu, Yongkang Gai, Dawei Jiang, Ping Lei and Xiaoli Lan

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2874;
You have access
Comparison of Tc-99m labeled PSMA-targeting HTK03180 and iPSMA for imaging prostate cancer with single photon emission computed tomography
Kelly Lu, Chengcheng Zhang, Zhengxing Zhang, Hsiou-Ting Kuo, Helen Merkens, Ruiyan Tan, Nadine Colpo, Francois Benard and Kuo-Shyan Lin

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2864;
You have access
A novel peptide-based 68Ga-PET radiotracer for TIGIT expression visualization
Rong Guo, Dinghu Weng, Haibo Xu, Dawei Jiang and Rui An

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2875;
You have access
Charged-linker modification of PSMA-617-based inhibitors affects the targeting and pharmacokinetic profile
Nicolas Geis, Yvonne Braunwarth, Nils Steinacker, Philipp Meyer, Matthias Eder and Ann-Christin Eder

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2880;
You have access
Synthesis, radiolabeling and in vivo evaluation of a 99mTc-labeled SPECT tracer for FAP imaging
Shreya Bendre, Zhengxing Zhang, Nadine Colpo, Jutta Zeisler, Francois Benard and Kuo-Shyan Lin

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2896;
You have access
Novel radiotracer targeting LDLR-overexpressing glioblastoma and pancreatic ductal adenocarcinoma – preclinical and dosimetry studies
Izabela Tworowska, Leo Flores II, Xuewei Qu, Cedric Malicet, Pascaline Lecorche, Ebrahim Delpassand and Jamal Temsamani

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2882;
You have access
89Zr-labeled anti-B7-H3 antibody for evaluating in vivo B7-H3 levels in a pulmonary melanoma mouse model
Haixun Guo

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2890;
You have access
Evaluation of dual-receptor targeted 68Ga-NGR-RGD in 8 different subcutaneous and orthotopic tumor models
Xiaoying Lv, Xiangming Song, Yu Long, Dexing Zeng, Yongkang Gai and Xiaoli Lan

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2883;
You have access
Development of 43Sc/47Sc-PSMA-617 as Theranostics for Prostate Cancer: Preliminary Cellular and Animal Studies
Jason Meier, Mohammed Bhuiyan, Hannah Zhang, Hsiu-Ming Tsai, Lucas Berens, Lara Leoni, Megan Mendez, Phillip Selman, Pavithra Kankanamalage, Thomas Brossard, Brittany Broder, Amy Renne, Matt Gott, John Greene, Jerry Nolen, Richard Freifelder, Walter Stadler, Ralph Weichselbaum, Chien-Min Kao, David Rotsch, Russell Szmulewitz and Chin-Tu Chen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2895;

Main menu

User menu

Search

More articles from Preclinical Probes for Oncology

Pages